| Q35011355 | A community-based epidemiological study of elevated serum alanine aminotransferase levels in Kinmen, Taiwan |
| Q24800420 | A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease |
| Q42991834 | A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. |
| Q40416496 | ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries |
| Q33775683 | Alanine aminotransferase decreases with age: the Rancho Bernardo Study |
| Q43040115 | Alanine aminotransferase flare-up in hepatitis C virus carriers with persistently normal alanine aminotransferase levels in a hyperendemic area of Japan. |
| Q26828819 | Alanine aminotransferase-old biomarker and new concept: a review |
| Q50627812 | Alanine transferase: An independent indicator of adiposity related comorbidity risk in youth. |
| Q36672592 | Aminotransferase levels are associated with cardiometabolic risk above and beyond visceral fat and insulin resistance: the Framingham Heart Study |
| Q21144283 | An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load |
| Q37131613 | Anti-HBc Screening of Blood Donors in Bangladesh: Relevance to Containment of HBV Propagation |
| Q37345958 | Assessing liver fibrosis. |
| Q57944892 | Association between body mass index and liver disorders: an epidemiological study |
| Q37323789 | Biomarkers of liver fibrosis |
| Q40708465 | Body mass index as a predictor of hepatic steatosis in living liver donors |
| Q44620386 | Body mass index is a good predictor of an elevated alanine transaminase level in the general population: hints from the Dionysos study. |
| Q58622691 | Chapter 4 Biomarkers Of Liver Fibrosis |
| Q33718958 | Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. |
| Q50587183 | Chronic hepatitis C viral infection in patients with normal serum alanine aminotransferases. |
| Q98159140 | Clinical Significance of Pre-to-Postoperative Dynamics of Aspartate Transaminase/Alanine Transaminase Ratio in Predicting the Prognosis of Renal Cell Carcinoma after Surgical Treatment |
| Q58765488 | Clinical and histopathological features of chronic hepatitis B virus infected patients with high HBV-DNA viral load and normal alanine aminotransferase level: A multicentre-based study in China |
| Q44151669 | Clinical management of HCV carriers with normal aminotransferase levels. |
| Q34225509 | Clinical significance of activity of ALT enzyme in patients with hepatitis C virus |
| Q45164428 | Clinical significance of elevated alanine aminotransferase in blood donors: a follow-up study |
| Q35628105 | Controversies in liver biopsy: who, where, when, how, why? |
| Q46718268 | Correlation between serum alanine aminotransferase activity and age: an inverted U curve pattern |
| Q45734380 | Cost effectiveness of screening for hepatitis C virus in asymptomatic, average-risk adults. |
| Q35058571 | Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence |
| Q33809532 | Definition of response to antiviral therapy in chronic hepatitis C. |
| Q35128204 | Determination of the upper cut-off values of serum alanine aminotransferase and aspartate aminotransferase in Chinese |
| Q37530123 | Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines |
| Q46914184 | Diagnostic value of FibroTest with normal serum aminotransferases |
| Q57363221 | Diurnal variation of serum alanine transaminase activity in chronic liver disease |
| Q46684874 | Effects of clinical laboratory choice on study outcome: an interlaboratory evaluation of aminotransferase levels |
| Q90727531 | Elevated serum levels of aminotransferases in relation to unhealthy foods intake: Tehran lipid and glucose study |
| Q37688129 | End points of therapy in chronic hepatitis B. |
| Q26780254 | Endocrine causes of nonalcoholic fatty liver disease |
| Q43244850 | Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury |
| Q38622926 | Estimation of Upper Limit of Normal for Serum Alanine Transaminase in Healthy South Indian Population |
| Q43159400 | Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. |
| Q38006136 | Evaluation of elevated liver enzymes |
| Q46831361 | FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C. |
| Q36537820 | First National Report on Aminotransaminases' Percentiles in Children of the Middle East and North Africa (MENA): the CASPIAN-III Study |
| Q45399020 | Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts |
| Q44381066 | HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy |
| Q60023612 | HLA class II favors clearance of HCV infection and progression of the chronic liver damage |
| Q36308734 | Healthy ranges of serum alanine aminotransferase levels in Iranian blood donors |
| Q36515750 | Hepatic Enzyme's Reference Intervals and Their Modulating Factors in Western Indian Population |
| Q36140671 | Hepatitis C virus infection: the new global epidemic |
| Q51011840 | High-free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance. |
| Q43038358 | Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). |
| Q46110185 | Histological changes in chinese chronic hepatitis B patients with ALT lower than two times upper limits of normal |
| Q27477959 | Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels |
| Q87074901 | Identifying practice gaps to optimize medical care for patients with nonalcoholic fatty liver disease |
| Q43292657 | Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. |
| Q37025213 | Impact of weight reduction program on serum alanine aminotransferase activity and immunologic response in obese hepatitis B patients |
| Q44666437 | Influence of age, sex, and degree of liver fibrosis on the association between serum alanine aminotransferase levels and liver inflammation in patients with chronic hepatitis C. |
| Q31083635 | Interferon for interferon naive patients with chronic hepatitis C. |
| Q73392899 | Interpretation of circulating C-reactive protein levels in adults: Body Mass Index and gender are a must |
| Q34312866 | Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors |
| Q45015609 | Is leptin associated with serum lipid profile or any other parameters of blood biochemistry in post-menopausal women with osteoporosis? |
| Q42873632 | Large-scale population analysis reveals an extremely low threshold for "non-healthy" alanine aminotransferase that predicts diabetes mellitus |
| Q37063901 | Liver enzyme alterations in HCV-monoinfected and HCV/HIV-coinfected patients |
| Q42580880 | Liver function tests as indicators of metabolic syndrome |
| Q38716877 | Low Alanine Aminotransferase Levels in the Elderly: Frailty, Disability, Sarcopenia and Reduced Survival |
| Q33242705 | Management of chronic hepatitis B virus infection: current perspectives for the nurse practitioner |
| Q44575341 | Metabolic factors are associated with serum alanine aminotransferase levels in patients with chronic hepatitis C. |
| Q37313574 | Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update |
| Q64891675 | Misconception: You Can't Have Liver Disease With Normal Liver Chemistries. |
| Q37868672 | Non-invasive assessment of fibrosis in liver grafts due to hepatitis C virus recurrence |
| Q30474738 | Non-invasive assessment of liver fibrosis in chronic hepatitis C. |
| Q38708566 | Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease |
| Q34892910 | Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B. |
| Q36449160 | Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C. |
| Q37347728 | Normal limit for serum alanine aminotransferase level and distribution of metabolic factors in old population of kalaleh, iran |
| Q33709267 | Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study |
| Q91131513 | Performance of Hepatic Artery Velocity in Evaluation of Causes of Markedly Elevated Liver Tests |
| Q26829883 | Persistent hypertransaminasemia in asymptomatic children: a stepwise approach |
| Q45245806 | Prevalence and etiology of persistently elevated alanine aminotransferase levels in healthy Iranian blood donors |
| Q33947985 | Prevalence of metabolic syndrome and risks of abnormal serum alanine aminotransferase in Hispanics: a population-based study. |
| Q83184829 | Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study |
| Q28482250 | Real time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort study |
| Q40234175 | Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? |
| Q45953743 | Reexamining transaminase elevation in Phase I clinical trials: the importance of baseline and change from baseline. |
| Q36609890 | Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity. |
| Q26828765 | Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome |
| Q86512409 | Revising the upper limit of normal for levels of serum alanine aminotransferase in a Middle Eastern population with normal liver histology |
| Q44131121 | Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation |
| Q35809610 | Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study |
| Q46682777 | Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease |
| Q34421198 | Serum alanine aminotransferase is correlated with hematocrit in healthy human subjects |
| Q40119930 | Serum aminotransferase activity and mortality risk in a United States community. |
| Q37690835 | Serum aminotransferase levels in healthy population from western India |
| Q47245264 | Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery |
| Q35782933 | Serum levels of alanine aminotransferase decrease with age in longitudinal analysis |
| Q37250779 | Serum γ-Glutamyltransferase, Alanine Aminotransferase and Aspartate Aminotransferase Activity in Healthy Blood Donor of Different Ethnic Groups in Gorgan |
| Q37278135 | Should chronic HBV infected patients with normal ALT treated: debate |
| Q37992183 | Should we treat HCV carriers with normal ALT levels? The '5Ws' dilemma |
| Q46613619 | Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women |
| Q43001619 | Subjects positive for hepatitis C virus RNA with normal aminotransferase levels, a "trompe l'oeil" clinical picture? |
| Q44236005 | Successful algorithm for selective liver biopsy in the right hepatic lobe live donor (RHLD). |
| Q43000081 | Sustained response to interferon-alpha2a monotherapy of young blood donors with minimal-to-mild chronic hepatitis C. The Donor Surveillance Study Group |
| Q38175460 | Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤ 40 IU/L and significant hepatic fibrosis |
| Q44825314 | The elusiveness of "normal" ALT in fatty liver |
| Q36121435 | The significance of isolated elevation of serum aminotransferases in infants and young children |
| Q50513280 | Upper limit of normal serum alanine and aspartate aminotransferase levels in Korea. |
| Q35713666 | Upper limits of normal for alanine aminotransferase activity in the United States population |
| Q53624130 | Variation in the hepatic gene expression in individual male Fischer rats. |
| Q58622652 | What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI) |